Vinblastine-associated pulmonary toxicity in patients receiving combination therapy with mitomycin and cisplatin

Two of 33 patients entered in a local pilot study of mitomycin, vinblastine, and cisplatin for non-small cell lung cancer developed vinblastine-associated pulmonary toxicity. As with other reports of vinca alkaloid-related pulmonary toxicity, the regimen included mitomycin. Based on these cases and others previously reported, the incidence of abrupt pulmonary toxicity following vinca alkaloid administration as part of mitomycin/vinca alkaloid combination appears to be three to six percent. Suggestions for management are given.

This article has been cited by other articles:

				M. S H Lam and R. J Ignoffo A guide to clinically relevant drug interactions in oncology Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85. [Abstract] [PDF]

				E. Briasoulis and N. Pavlidis Noncardiogenic Pulmonary Edema: An Unusual and Serious Complication of Anticancer Therapy Oncologist, April 1, 2001; 6(2): 153 - 161. [Abstract] [Full Text]

				M. A. JANTZ and S. A. SAHN Corticosteroids in Acute Respiratory Failure Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1079 - 1100. [Full Text]